Skip to main content
. Author manuscript; available in PMC: 2024 Feb 15.
Published in final edited form as: Cancer Res. 2023 Aug 15;83(16):2750–2762. doi: 10.1158/0008-5472.CAN-22-3646

Figure 1. Alkylating agent sensitizes ARID1A-KO cells to Olaparib.

Figure 1.

(A) Viabilities of hEM3 ARID1A-WT and ARID1A-KO cells. Cells were treated with the indicated chemotherapeutic drugs agents in the presence of 5 μM Olaparib (Olap). **P < 0.01, ***P < 0.001, ****P < 0.001, Student’s t-test.

(B) Viability of hEM3 and OVCA429 ARID1A-WT or ARID1A-KO cells assessed in the presence of 100 μM temozolomide (TMZ) in combination with serially increased doses of Olaparib. ***P < 0.001, ****P < 0.001, Student’s t-test.